By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Crown Bioscience, Inc. 

4008 Burton Drive

Santa Clara  California  95054  U.S.A.
Phone: 617-818-2285 Fax: 408-986-0019

Crown Bioscience, Inc. is a premium biology CRO, providing discovery and early development solutions for global biotech and pharmaceutical companies. It is headquartered in the Silicon Valley, with wholly owned research centers in Beijing, China and Indianapolis. Crown Bioscience is the leader in providing high-quality and cost-effective services in preclinical oncology. Our services include target protein expression, purification and crystallization, in vitro/in vivo pharmacology, non-GLP toxicology, PK/PD, and translational research with patient-derived cell lines and animal models.

For more information, please visit our web site at

Key Statistics

Ownership: Private

Web Site: Crown Bioscience



Company News
Crown Bioscience Is One of Several Life Science Companies Planning Taiwan IPO 7/29/2016 1:16:16 PM
Crown Bioscience Expands U.S. Ops in San Diego, Establishes Center of Excellence for Oncology 7/21/2016 6:12:37 AM
Crown Bioscience, Inc. Announces Launch Of OmniScreen Cell Panel Screening Platform 7/7/2016 6:17:00 AM
Crown Bioscience, Inc. Introduces New Recombinant Cell Lines For Oncology Drug Discovery 6/30/2016 8:10:33 AM
Crown Bioscience, Inc. Announces Strengthening Of Global Immuno-Oncology Platform With Immunophenotyping Service Offering 6/16/2016 10:53:12 AM
Crown Bioscience, Inc. Showcasing New Models And Services At The 76th American Diabetes Association Meeting 6/2/2016 9:36:47 AM
Crown Bioscience, Inc. Launching OncoExpress Technology At ASCO Meeting 5/24/2016 8:52:59 AM
Crown Bioscience, Inc. Launches HuScreen A New High Throughput Service Platform Utilizing The Largest Available Collection Of PDX Models 5/19/2016 10:05:20 AM
Crown Bioscience, Inc. Announces The Establishment Of Unique EGFR-Mutated Non-Small Cell Lung Cancer Models 5/10/2016 6:50:21 AM
Crown Bioscience, Inc. Launches MuScreen Platform For Evaluating In Vivo Efficacy Of Immuno-Oncology Agents 4/26/2016 8:08:07 AM